Microbiome Sample Preparation Technology Market Report 2022: Rising Prevalence of Infectious Disease Fueling Demand
01 déc. 2022 07h43 HE | Research and Markets
Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Sample Preparation Technology Market Share, Size, Trends, Industry Analysis Report, By Product; By Workflow; By Application; By Disease; By...
22157.jpg
2022 Insights on the Microbiome Therapeutics Global Market: Anticipated Future Developments and Trends
01 déc. 2022 06h48 HE | Research and Markets
Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions,...
22157.jpg
Global Microbiome Therapeutics Market Report 2022: Increasing Focus on Human Microbiome Therapeutics Development from Academics, Researchers & Biotechnology Firms
22 nov. 2022 05h43 HE | Research and Markets
Dublin, Nov. 22, 2022 (GLOBE NEWSWIRE) -- The "Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (FMT v/s Microbiome...
Finch_Short_Logo_L.png
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
10 nov. 2022 07h00 HE | Finch Therapeutics Group, Inc.
Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDITopline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE...
Summit-logo-RGB.png
Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
09 nov. 2022 08h30 HE | Summit Therapeutics Inc.
Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on...
Finch_Short_Logo_L.png
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
09 nov. 2022 08h00 HE | Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Global Human Microbiome Market Report 2022: Rising Focus on the Development of Therapeutics Driving Growth
02 nov. 2022 06h03 HE | Research and Markets
Dublin, Nov. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Human Microbiome Market Size, Share & Industry Trends Analysis Report By Product, By Disease Type, By Technology, By Application, By Type,...
AXIAL Logo 2021MAR05.png
Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022
01 nov. 2022 08h00 HE | Axial Therapeutics
WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
Intrinsic Medicine Logo 1.png
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders
31 oct. 2022 08h00 HE | Intrinsic Medicine
Intrinsic’s pipeline consists of drug candidates based on human milk oligosaccharides (HMOs), which are bioactive small molecules that naturally occur in human milk, with the potential to transform...
Finch_Short_Logo_L.png
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
24 oct. 2022 08h00 HE | Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...